Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PYRUKYND safely and effectively. See full prescribing information for PYRUKYND. PYRUKYND ®(mitapivat) tablets, for oral use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
- generic_name
- mitapivat
- product_names
- mitapivat
- ndc
- 71334-205, 71334-205-14, 71334-205-05, 71334-210, 71334-210-14, 71334-210-20, 71334-215, 71334-215-14, 71334-215-50, 71334-220, 71334-220-11, 71334-225, 71334-225-12, 71334-210-07, 71334-205-07, 71334-230, 71334-230-13, 71334-215-07
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en